Spyre Therapeutics reported its first major Phase 2 results for SPY001 in ulcerative colitis, setting the company up to compete against newer integrin-pathway approaches entering the clinic. In the SKYLINE study, SPY001 met the trial’s primary objective at 12 weeks, showing a 9.2-point reduction on a disease activity scoring system. Spyre said the data were statistically significant and also showed endoscopic improvements, alongside a reported 40% remission rate at 12 weeks. The company noted one severe adverse event—chest pain in a patient with cardiovascular history—reported as unrelated to treatment. SPY001 targets the α4β7 inflammation pathway, aligning with a class competitive landscape shaped by integrin-directed biologics. Spyre is testing multiple therapies in the broader Phase 2 program, with later placebo-controlled data expected in 2027.